Ser677

Site Information
EIEKIMSsIGEGIDF SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4710057

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 )
Disease tissue studied:	breast cancer ( 2 , 5 , 9 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 5 ) , lung cancer ( 9 ) , non-small cell lung cancer ( 9 ) , ovarian cancer ( 5 ) , melanoma skin cancer ( 3 ) , teratoma ( 11 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 12 ) , 293 (epithelial) ( 4 ) , 293E (epithelial) ( 10 ) , breast ( 1 , 5 ) , BT-20 (breast cell) ( 9 ) , Calu 6 (pulmonary) ( 9 ) , H2077 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC366 (pulmonary) ( 9 ) , HCC78 (pulmonary) ( 9 ) , HeLa (cervical) ( 8 ) , HOP62 (pulmonary) ( 9 ) , Jurkat (T lymphocyte) ( 6 , 13 ) , K562 (erythroid) ( 8 ) , MCF-7 (breast cell) ( 2 ) , MDA-MB-468 (breast cell) ( 9 ) , NCCIT (epithelial) ( 11 ) , NCI-H1568 (pulmonary) ( 9 ) , NCI-H1648 (pulmonary) ( 9 ) , NCI-H322 (pulmonary) ( 9 ) , NCI-H647 (pulmonary) ( 9 ) , ovary ( 5 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:	ischemia ( 5 ) , Torin1 ( 10 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54 24965592 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
8	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
9	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
10	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
11	Zhou J (2010) CST Curation Set: 9672; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
12	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
13	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info